ERBB2 and breast carcinoma: In addition, use of the BRD4 inhibitor JQ1 in combination with the EGFR inhibitor lapatinib has been shown to suppress lapatinib-induced kinome reprogramming in ERBB2+ breast cancer cells, where other kinase inhibitor combinations could not5.